Vendor, Chicago, IL
Iit Research Institute
UEI DGBUFQYMKWB5, CAGE 03889
36 awards and $9,538,807 obligated between January 3, 2024 and September 28, 2026, 100% under full and open competition, against 6.7 offers on average where reported. 8 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| National Institutes of Health | $9,668,239 |
| Food and Drug Administration | $0 |
| Office of Assistant Secretary for Preparedness and Response | -$129,432 |
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $9,304,901 |
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $1,156,161 |
| Other Scientific and Technical Consulting ServicesNAICS 541690 | -$91,999 |
| Professional, Scientific, and Technical ServicesNAICS 541711 | -$93,336 |
| Professional, Scientific, and Technical ServicesNAICS 541712 | -$736,920 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 36 |
| Delivery Order | 26 |
| Definitive Contract | 1 |
Hear when Iit Research Institute wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Iit Research Institute holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 4
- Obligated so far
- $4,278,653
- Soonest
- October 31, 2026
The 4 contracts, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,369,442 |
| Westat, Inc.Rockville, MD | $760,724,225 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,758,507 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- PREVENT IDIQ MATO RFP
National Institutes of Health, NIH NCI
SolicitationNAICS 541714Anywhere in the US75N91023R00024Awarded to Iit Research Institute for $149,995,000
Posted Sep 16, 20246 publications - Safety Evaluation and Toxicology Studies and Related Services for Drug Development
National Institutes of Health, National Institutes of Health Nida
Award noticeNAICS 541715Chicago, IL75N95024D00020Awarded to Iit Research Institute for $48,622,546
Posted Aug 13, 2024
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N98026F00001Delivery Order, June 26, 2026, Full and Open Competition | National Institutes of Health OlaoNational Institutes of Health | Task Order Award- SSL GLP and NON-GLP Toxicology StudiesNAICS 541715, PSC AJ11 | $3,391,980 |
| 75N91024F00002Delivery Order, June 10, 2024, Full and Open Competition | NIH NCINational Institutes of Health | Toxicology Studies in Mice and Dogs Administered MTX-531NAICS 541715, PSC AN12 | $1,790,042 |
| 75N91022C00010Definitive Contract, January 29, 2024, Full and Open Competition, 4 offers | NIH NCINational Institutes of Health | Preclinical Toxicology of Large Molecule Drugs Developed for Cancer and Other IndicationsNAICS 541715, PSC AN12 | $1,246,165 |
| 75N91020F00001Delivery Order, April 4, 2024, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Task Order Title: Preclinical Development of an Rna Vaccine for Immunoprevention of Prostate CancerNAICS 541714, PSC AN12 | $1,014,245 |
| 75N91024F00003Delivery Order, September 6, 2024, Full and Open Competition | NIH NCINational Institutes of Health | Toxicology Studies in Rats and Dogs Administered AIT-102NAICS 541715, PSC AN12 | $627,793 |
| 75N95024F00002Delivery Order, September 16, 2024, Full and Open Competition, 4 offers | National Institutes of Health NidaNational Institutes of Health | First-In-Class Small Molecule Candidate Ncgc72 (CD206 Agonist) for Immunologically Cold Solid Organ CancersNAICS 541715, PSC AN11 | $547,006 |
| 75N95024F00002Delivery Order, March 1, 2024, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | Iitri - PTTP DRF BPN Study - TO3NAICS 541715, PSC AJ11 | $438,148 |
| 75N95025F00001Delivery Order, September 25, 2025, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | PTTP Task Order - Iitri - MS Rodent and Non-Rodent MTD-DRF StudiesNAICS 541715, PSC AJ11 | $401,373 |
| 75N95024F00003Delivery Order, March 14, 2024, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | Iitri -Dog MTD-DRF Studies-To 4NAICS 541715, PSC AJ11 | $224,716 |
| 75N95024F00001Delivery Order, March 1, 2024, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | Iitri - Performance Area 1 TO2NAICS 541715, PSC AJ11 | $212,495 |
| 75N95024F00004Delivery Order, July 23, 2024, Full and Open Competition | National Institutes of Health NidaNational Institutes of Health | Iitri - NON-GLP Dose Range Finding (Drf) Studies-Dec. 2023 #2NAICS 541715, PSC AJ11 | $201,969 |
| 75N95020F00001Delivery Order, February 2, 2024, Full and Open Competition, 3 offers | National Institutes of Health NidaNational Institutes of Health | Non-Clinical Safety of Pth-Ia, Inverse Agonist, to Support Jansen Metaphyseal Chondrodysplasia (Jmc) Disease.NAICS 541712, PSC AN11 | $166,060 |
| 75N91020F00001Delivery Order, May 8, 2024, Full and Open Competition, 2 offers | NIH NCINational Institutes of Health | Task Order: Topical Resatorvid for Nonmelanoma Skin Cancer PreventionNAICS 541714, PSC AN12 | $147,609 |
| 75N95020F00002Delivery Order, February 20, 2024, Full and Open Competition, 4 offers | National Institutes of Health NidaNational Institutes of Health | Non-Clinical Safety of Mitragynine to Support Its Future Oral Therapy for Analgesia Indication.NAICS 541712, PSC AN11 | $143,468 |
| 75N98026F00002Delivery Order, September 11, 2026, Full and Open Competition | National Institutes of Health OlaoNational Institutes of Health | Iitri - PA1 Task Order #07NAICS 541715, PSC AJ11 | $108,506 |
| 75N91026F00001Delivery Order, February 6, 2026, Full and Open Competition | NIH NCINational Institutes of Health | Toxicology Studies in Mice Administered MTX-531 - Final DeliverablesNAICS 541715, PSC B599 | $68,323 |
| 75N98026F00003Delivery Order, September 16, 2026, Full and Open Competition | National Institutes of Health OlaoNational Institutes of Health | Iitri - 2026 SF Ind-Enabling GLP Toxicology StudiesNAICS 541715, PSC AJ11 | $46,385 |
| 75N91018F00005Delivery Order, January 3, 2024, Full and Open Competition, 2 offers | NIH NCINational Institutes of Health | Lfa (Mpges-1/5-Lox Inhibitor): Preclinical Studies to Support a Clinical Trial.NAICS 541711, PSC R499 | $36,096 |
| 75N91022F00001Delivery Order, April 30, 2025, Full and Open Competition | NIH NCINational Institutes of Health | Contract Orientation & Kickoff Meeting for R&D Services Under "preclinical Toxicology of Small Molecule Drugs Developed for Cancer and OtherNAICS 541715, PSC AN12 | $0 |
| 75N95022F00001Delivery Order, September 18, 2024, Full and Open Competition, 3 offers | National Institutes of Health NidaNational Institutes of Health | Non-Clinical Safety Assessment of Covalent BI-TOX to Support Neuropathic Pain IndicationNAICS 541712, PSC AN11 | $0 |
| 75N91019D00012December 17, 2024, Full and Open Competition, 9 offers | NIH NCINational Institutes of Health | Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate BiomarkersNAICS 541714, PSC AN12 | $0 |
| 75N91019D00013December 18, 2024, Full and Open Competition, 4 offers | NIH NCINational Institutes of Health | Prevent Preclinical Drug Development Program: Toxicology and Pharmacology Testing"NAICS 541714, PSC AN12 | $0 |
| 75N91022D00016May 9, 2024, Full and Open Competition, 5 offers | NIH NCINational Institutes of Health | Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other IndicationsNAICS 541715, PSC AN12 | $0 |
| 75N91024D00001January 23, 2024, Full and Open Competition, 9 offersSolicitation | NIH NCINational Institutes of Health | Prevent Cancer Preclinical Drug Development Program: Toxicology and Pharmacology TestingNAICS 541714, PSC AN12 | $0 |
| 75N93024D00012July 10, 2024, Full and Open Competition, 76 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Pre-Clinical Models of Infectious Diseases - Task Areas a and BNAICS 541714, PSC AN11 | $0 |
| 75N95021D00026February 27, 2024, Full and Open Competition, 1 offers | National Institutes of Health NidaNational Institutes of Health | Id/Iq Parent Award for Pharmacology and Toxicology for Therapeutics Program (Pttp)NAICS 541715, PSC AJ11 | $0 |
| 75N95024D00020June 20, 2024, Full and Open Competition, 6 offersSolicitation | National Institutes of Health NidaNational Institutes of Health | Safety Evaluation and Toxicology Studies and Related Services for Drug DevelopmentNAICS 541715, PSC AN11 | $0 |
| HHSF223201510000IJuly 23, 2026, Full and Open Competition, 4 offers | FDA Office of Acq Grant SVCSFood and Drug Administration | In Vitro Toxicology of Tobacco and Related ProductsNAICS 541712, PSC AJ11 | $0 |
| HHSN261201500024IDecember 18, 2024, Full and Open Competition, 7 offers | NIH NCINational Institutes of Health | Preclinical Prevent Toxicology and PharmacologyNAICS 541711, PSC R499 | $0 |
| 75N91021F00001Delivery Order, July 9, 2024, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Evaluation of Afpep for the Prevention of Breast CancerNAICS 541714, PSC AN12 | -$2,781 |
| 75N95019F00090Delivery Order, March 5, 2024, Full and Open Competition, 3 offers | National Institutes of Health NidaNational Institutes of Health | GLP 28 Day Toxicity Study of ACT-1 When Applied Topically to Eyes Twice Daily for 28 Days in Dogs with a 14 Day Recovery Period. Pop: 09/01/NAICS 541712, PSC AN11 | -$2,908 |
| 75N91023F00001Delivery Order, April 2, 2024, Full and Open Competition, 2 offers | NIH NCINational Institutes of Health | Base Title: Prevent Preclinical Pharmacology and Toxicology Task Order Title: Nicotine Reduction Therapy Using the Human Monoclonal AntibodyNAICS 541714, PSC AN12 | -$2,912 |
| 75N95019F00091Delivery Order, April 10, 2024, Full and Open Competition, 4 offers | National Institutes of Health NidaNational Institutes of Health | Non-Clinical Safety Assessment of Acoziborole (Scyx-7158) to Support Human African Trypanosomiasis (Hat or "sleeping Sickness"). Pop: 09/01/NAICS 541712, PSC AN11 | -$35,321 |
| HHSN26100003Delivery Order, September 28, 2026, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | To Deobligate Unused FY21 Expiring FundsNAICS 541690, PSC R499 | -$91,999 |
| 75A50118F33002Delivery Order, September 29, 2025, Full and Open Competition, 2 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Modification to De-Obligate Expiring FY19 FundsNAICS 541711, PSC AN13 | -$129,432 |
| 75N95020F00003Delivery Order, April 11, 2024, Full and Open Competition, 4 offers | National Institutes of Health NidaNational Institutes of Health | Non-Clinical Safety Assessment of Drinabant, a Cannabinoid Receptor (CB-1) Antagonist, for Acute Cannabinoid Overdose (Aco)NAICS 541712, PSC AN11 | -$1,008,219 |
- Places of performance
- Illinois
- Product and service codes
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic ResearchAN12 Health R&D Services; Health Care Services; Applied ResearchB599 Other Special Studies and AnalysisR499 Other Professional ServicesAN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 98 across 36 awards